MF Capital Portfolio Company — Dearer Medical Completes Series C Financing and Files IPO Prospectus

Mingfeng Capital's Portfolio Company — DEARER (Shanghai Dier Medical Device Co., Ltd.) recently completed its Series C financing. In June last year, DEARER announced the signing of an IPO tutoring agreement, officially launching its IPO process.

About DEARER

DEARER is one of the largest R&D, design, and manufacturing enterprises for cosmetic contact lenses in China. DEARER has been committed to product innovation, continuously increasing investment in R&D innovations, including the development of cosmetic lens design techniques, new material research, high-precision mold development, and automation equipment R&D. It has achieved multiple research outcomes and holds 11 invention patents, such as internal surface coating and silicone hydrogel, 57 utility model patents, and 7 design patents. Currently, it holds a leading position in the industry in terms of comprehensive capabilities in the design and production of colored contact lenses.

Currently, the company holds 30 Class III medical device registration certificates, including 11 Class III medical device registration certificates in China and 19 Class III medical device registration certificates in South Korea, covering the full range of contact lens products such as daily disposables, monthly disposables, half-yearly disposables, and yearly disposables. In China, the company owns 10 colored contact lens medical device registration certificates (including one silicone hydrogel daily disposable colored lens registration certificate) and one regular contact lens medical device registration certificate. Among the 19 Class III medical device registration certificates held in South Korea, three are for silicone hydrogel products, including registration certificates for daily disposable colored lenses, transparent lenses, and monthly disposable colored lenses.

In terms of production capacity, DEARER has successively established Jilin Realcon Contact Lens Co., Ltd., Suzhou Realcon Technology Co., Ltd., South Korea Foco Co., Ltd., Xi'an Keshimei Optical Technology Co., Ltd., and Shanghai DEARER Weizhen Medical Device Co., Ltd. Among them, Shanghai DEARER Weizhen Medical Device Co., Ltd. is its largest future production base, with a plant area of 68,000 square meters and an annual production capacity of up to 1 billion pieces. It is expected to be completed in 2024 and put into operation in 2025.

(source: DEARER）

About MF

Mingfeng Capital is a qualified private equity manager registered with the Asset Management Association of China, with current investments and management scale nearing 1 billion. Since its registration in March 2016, it has successively established offices in Chengdu and Beijing. Mingfeng Capital has consistently focused on the consumer healthcare sector, particularly investments in the medical aesthetics sub-sector. Through years of deep cultivation, Mingfeng Capital has invested in high-quality enterprises such as Aibo Medical (688050), Chengdu Eight Places Medical Beauty Hospital, Ruiang Gene (688217), JunShengTai, Green Bamboo Biotech (HK2480), Jinbo Biotech (832982), Giant Bio (HK2367), Chuangjian Medical, Jiangsu Chuangying, DEARER, Behope Weikang, Lanwei Medicine, Yuxi Pharmaceutical, Zhiprotein Biotech, Ruihua Kangyuan, and Shengzhi Runhe.